Genevieve Pate
Family · Quilcene, WANPI 1376056622
Payments from drug & device makers
Across 214 payments — averaging $19.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$756
- Novo Nordisk$641
- Lilly USA, LLC$355
- AstraZeneca$286
- Johnson & Johnson$236
- Amgen$231
- plus $2K from 22 others
What the payments were for
- Travel & lodging$511%
- Food & beverage$4,06697%
- Gifts$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 34 | $756 |
| Novo Nordisk | 31 | $641 |
| Lilly USA, LLC | 22 | $355 |
| AstraZeneca | 15 | $286 |
| Johnson & Johnson | 9 | $236 |
| Amgen | 14 | $231 |
| GSK | 8 | $181 |
| Biohaven Pharmaceutical Holding Company Ltd. | 7 | $172 |
| Antares Pharma, Inc. | 10 | $165 |
| Amarin Pharma, Inc. | 8 | $151 |
| Boehringer Ingelheim | 5 | $131 |
| Biohaven Pharmaceuticals, Inc. | 9 | $123 |
| Eisai Inc. | 5 | $88 |
| Esperion Therapeutics, Inc. | 5 | $87 |
| Abbott | 4 | $79 |
| Bayer | 3 | $66 |
| Mannkind Corporation | 1 | $59 |
| Teva Pharmaceuticals USA, Inc. | 3 | $58 |
| Sunovion Pharmaceuticals Inc. | 5 | $51 |
| Novartis | 3 | $48 |
| Pfizer | 3 | $45 |
| Astellas Pharma US Inc | 2 | $39 |
| Arbor Pharmaceuticals, Inc. | 3 | $38 |
| Jazz Pharmaceuticals Inc. | 1 | $24 |
| Idorsia Pharmaceuticals US Inc | 1 | $20 |
| Nestle Healthcare Nutrition Inc. | 1 | $19 |
| Acerus Pharmaceuticals Corporation | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,177 in reported general payments places this provider in the 95th percentile of 1,706 family providers in Washington.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 38 | $42,548 |
| EliquisApixaban | 32 | $35,854 |
| MounjaroTirzepatide | 16 | $16,673 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 13 | $9,069 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $7,699 |
| PaxlovidNirmatrelvir/Ritonavir | 14 | $5,509 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $5,040 |
| Aripiprazole OdtAripiprazole | 12 | $3,928 |
| OxycontinOxycodone Hcl | 12 | $3,522 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 18 | $2,071 |
| Duloxetine Hcl | 42 | $1,503 |
| Atorvastatin Calcium | 169 | $1,492 |
| Lidocaine | 19 | $1,476 |
| Ventolin HfaAlbuterol Sulfate | 23 | $1,361 |
| Levothyroxine Sodium | 128 | $1,231 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Combivent Respimat | $131 | $51,61751 claims |
| PfizerEliquis, Paxlovid | $45 | $41,36346 claims |
| Lilly USA, LLCMounjaro | $355 | $16,67316 claims |
| GSKBreo Ellipta, Anoro Ellipta | $181 | $12,73930 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $58 | $38911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,706 family providers in Washington.
Other family in Quilcene
- Patric SchineCentralia$842K
- Sharla PetersonKenmore$192K
- Zelda SwainSpokane$83K
- Savannah MorganRenton$76K
- Kevan PettersonSeattle$56K
- Kelly McFeeSunnyside$42K
- Cheryl SomersSpokane$31K
- Hye-Jin GehringBellevue$30K
- Kaitlin BrasierSeattle$29K
- Karen JohnsonSeattle$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.